

# What Is New in Lymphoma?

Ca-A Cancer Journal for Clinicians

54, 260-272

DOI: [10.3322/canjclin.54.5.260](https://doi.org/10.3322/canjclin.54.5.260)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Rarity gives a charm: evaluation of trace proteins in plasma and serum. <i>Expert Review of Proteomics</i> , 2005, 2, 393-406.	1.3	16
2	Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2005, 16, 1352-1358.	0.6	48
3	Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas. <i>BioDrugs</i> , 2006, 20, 13-23.	2.2	24
4	Initial evaluation of <sup>227</sup> Th-p-benzyl-DOTA-rituximab for low-dose rate $\beta$ -particle radioimmunotherapy. <i>Nuclear Medicine and Biology</i> , 2006, 33, 271-279.	0.3	55
5	Recent advances in haematology and oncology: graft-versus-host disease, classification and treatment of non-Hodgkin's lymphomas, and sentinel-node biopsy in breast cancer.. <i>Clinical and Experimental Dermatology</i> , 2006, 31, 169-172.	0.6	0
6	Marek's disease virus: from miasma to model. <i>Nature Reviews Microbiology</i> , 2006, 4, 283-294.	13.6	343
7	Current controversies in follicular lymphoma. <i>Blood Reviews</i> , 2006, 20, 179-200.	2.8	12
8	Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. <i>Annals of Hematology</i> , 2006, 85, 257-262.	0.8	16
9	Introduction to B-Cell Disorders. <i>Clinical Journal of Oncology Nursing</i> , 2007, 11, 3-12.	0.3	1
10	PKC $\delta$ expression contributes to the resistance of hodgkin's lymphoma cell lines to apoptosis. <i>Cancer Biology and Therapy</i> , 2007, 6, 1371-1376.	1.5	27
11	Hodgkin's and Non-Hodgkin's Lymphomas. <i>Radiologic Clinics of North America</i> , 2007, 45, 69-83.	0.9	29
12	The Impact of High-dose Sodium Selenite Therapy on Bcl-2 Expression in Adult Non-Hodgkin's Lymphoma Patients: Correlation with Response and Survival. <i>Biological Trace Element Research</i> , 2007, 120, 1-10.	1.9	28
13	Expression of PLK1 and survivin in non-Hodgkin's lymphoma treated with CHOP. <i>Acta Pharmacologica Sinica</i> , 2008, 29, 371-375.	2.8	10
14	Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. <i>Journal of Hepatology</i> , 2008, 49, 557-563.	1.8	68
15	Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 187 Td (Arabinosid Refractory Lymphoma. <i>Cancer Investigation</i> , 2008, 26, 401-406.	0.6	41
16	<sup>18</sup> F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2008, 49, 13-21.	2.8	142
17	Vitamin D and Non-Hodgkin Lymphoma Risk in Adults: A Review. <i>Cancer Investigation</i> , 2009, 27, 942-951.	0.6	17
18	Bendamustine therapy in chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1687-1698.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Aspects of Bâ€Cell Nonâ€Hodgkinâ€™s Lymphoma Development: A Transition from Immuneâ€Reactivity to Malignancy. Scandinavian Journal of Immunology, 2009, 69, 387-400.	1.3	22
21	Application of MALDI imaging for the diagnosis of classical Hodgkin lymphoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1651-1655.	1.2	32
22	Luteinizing Hormone Receptor Deficiency Increases the Susceptibility to Alkylating Agent-Induced Lymphomagenesis in Mice. Hormones and Cancer, 2010, 1, 256-264.	4.9	1
23	Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. , 2011, , CD007941.		39
25	Natural Killer Cell Immunoglobulin-like Receptor (KIR) genotypes in Follicular Lymphoma patients: Results of a pilot study. Gene, 2013, 525, 136-140.	1.0	5
26	HLA Class I allele frequencies in the Lebanese population. Gene, 2013, 512, 560-565.	1.0	7
27	Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. The Cochrane Library, 2017, 5, CD007941.	1.5	47
28	Efficacy and safety of new direct antiviral agents in hepatitis C virusâ€infected patients with diffuse large Bâ€cell nonâ€Hodgkin's lymphoma. Hepatology, 2018, 67, 48-55.	3.6	76
29	Gene Expression Profiling in Malignant Lymphomas. , 2007, 593, 134-146.		8
30	The Role of TGF-Î² in Bleomycin Induced Pulmonary Fibrosis. , 2008, , 581-594.		2
31	Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma. Medicine (United Tj ETQq0 0 0 qgBT /Overlock 10 Tf		4
32	Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma. Advanced Biomedical Research, 2017, 6, 30.	0.2	6
33	Lymphoma and Autoimmune Disease. , 2006, , 971-985.		0
35	Hematologic Disorders. , 2009, , 571-612.		0
36	A Retrospective Study of Efficacy and Toxicities of Rituximab in Combination with Chemotherapy for NHL patients in Bangladesh. Anwer Khan Modern Medical College Journal, 2015, 6, 28-34.	0.1	0